Healthcare Services

Genome-Wide Association Studies Market Growth Expected to Reach $4.25 Billion by 2030 with 13.4% CAGR

April 1, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Increase Is Anticipated For The Genome-Wide Association Studies Market Over The 2026–2030 Period?

The genome-wide association studies market size has experienced rapid growth in recent years. It is forecast to grow from $2.27 billion in 2025 to $2.58 billion in 2026, achieving a compound annual growth rate (CAGR) of 13.7%. This expansion in the past can be attributed to the broadening of genetic research initiatives, enhanced availability of genomic datasets, an increase in academic population studies, the rising adoption of genotyping technologies, and advancements in data analysis capabilities.

The market for genome-wide association studies is projected to experience substantial expansion over the upcoming years. This market is set to reach a value of $4.26 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 13.4%. This anticipated growth during the forecast period is primarily driven by factors such as the heightened demand for insights into precision medicine, an uptick in investments dedicated to genomic analytics platforms, the broadening of AI-driven genetic research, increasing pharmaceutical engagement in discovering new drug targets, and a strengthened emphasis on predictive healthcare models. Key trends anticipated during this period encompass the greater adoption of extensive population genomics studies, an increase in the utilization of sophisticated bioinformatics platforms, the expanding incorporation of GWAS into drug discovery processes, the proliferation of personalized medicine research initiatives, and a more concentrated effort on predicting disease risk.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=28234&type=smp

Which Major Factors Are Driving The Expansion Of The Genome-Wide Association Studies Market?

The expanding need for personalized medicine is anticipated to fuel the growth of the genome-wide association studies market in the coming years. Personalized medicine is a healthcare strategy that customizes treatment and prevention methods based on an individual’s distinct genetic makeup, lifestyle, and environmental factors. The rising acceptance of personalized medicine largely stems from progress in genomics, which allows for the accurate detection of genetic variations and the development of customized treatments. Genome-wide association studies (GWAS) play a crucial role in advancing personalized medicine by pinpointing genetic variations associated with various diseases, thereby facilitating targeted therapeutic approaches. These studies enhance healthcare results by offering insights into individual risk profiles and fostering precision therapies. As an illustration, in February 2024, the Personalized Medicine Coalition (PMC), a US-based nonprofit organization, reported that the U.S. Food and Drug Administration (FDA) sanctioned 26 new personalized medicines in 2023, which represents a substantial rise from the 12 approved in 2022. Consequently, the escalating demand for personalized medicine is a key impetus behind the expansion of the genome-wide association studies market.

How Is The Genome-Wide Association Studies Market Segmented Across Key Categories?

The genome-wide association studies market covered in this report is segmented –

1) By Product Type: Genotyping Services, Genotyping Kits And Reagents, Software And Data Analysis Tools, Other Product Types

2) By Application: Drug Discovery, Disease Risk Assessment, Personalized Medicine, Other Applications

3) By End-User: Pharmaceutical And Biotechnology Companies, Academic And Research Institutes, Hospitals And Clinics, Other End-Users

Subsegments:

1) By Genotyping Services: Whole Genome Sequencing (Wgs), Exome Sequencing, Targeted Genotyping

2) By Genotyping Kits And Reagents: Dna Extraction Kits, Sequencing Reagents, Library Preparation Kits

3) By Software And Data Analysis Tools: Bioinformatics Platforms, Data Visualization Tools, Statistical Analysis Software

4) By Other Product Types: Sample Collection Devices, Quality Control Tools, Laboratory Consumables

What Trends Are Advancing Progress In The Genome-Wide Association Studies Market?

Leading companies in the genome-wide association studies market are concentrating on developing innovative solutions, such as sophisticated research platforms, to accelerate disease discovery and personalized medicine applications. Such a platform functions as an integrated system of tools and technologies, enabling large-scale genomic data generation, analysis, and interpretation specifically for genome-wide association studies. For example, in January 2025, 23andMe Holding Co., a US-based biotechnology company, launched Discover23, a consumer-facing platform offering genetic insights and ancestry exploration. This platform also allows biopharma collaborators to access comprehensive genetic data through a trusted environment powered by Lifebit. It provides analysis-ready genome-wide association studies (GWAS) on over 1,000 disease cohorts, which are derived from billions of phenotypic data points from millions of consenting participants. The advanced research platform’s goal is to accelerate drug discovery by assisting researchers in identifying novel disease biology and potential drug targets, and to improve clinical trial success while maintaining participant privacy.

Who Are The Dominant Players Shaping The Genome-Wide Association Studies Market Landscape?

Major companies operating in the genome-wide association studies market are F. Hoffmann-La Roche AG, AstraZeneca plc, Thermo Fisher Scientific Inc., GlaxoSmithKline plc, Regeneron Pharmaceuticals Inc., Eurofins Scientific SE, Laboratory Corporation of America Holdings, Daiichi Sankyo Company Limited, Agilent Technologies Inc., Illumina Inc., Revvity Inc., QIAGEN N.V., Databricks Inc., Broad Institute of MIT and Harvard, BGI Genomics Co. Ltd., deCODE genetics Inc., Genomics England Ltd., CD Genomics Inc., Veritas Genetics Inc., Finngen, The Wellcome Sanger Institute

Read the full genome-wide association studies market report here:

https://www.thebusinessresearchcompany.com/report/genome-wide-association-studies-global-market-report

Which Region Currently Holds The Largest Share Of The Genome-Wide Association Studies Market?

North America was the largest region in the genome-wide association studies market in 2025. The regions covered in the genome-wide association studies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Genome-Wide Association Studies Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=28234&type=smp

Browse Through More Reports Similar to the Global Genome-Wide Association Studies Market 2026, By The Business Research Company

Gene Editing Global Market Report

https://www.thebusinessresearchcompany.com/report/gene-editing-global-market-report

Crispr Gene Editing Global Market Report

https://www.thebusinessresearchcompany.com/report/crispr-gene-editing-global-market-report

Gene Synthesis Global Market Report

https://www.thebusinessresearchcompany.com/report/gene-synthesis-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795